Having trouble accessing articles? Reset your cache.

InterMune, Roche sales and marketing update

InterMune sold all rights to HCV candidate danoprevir to partner Roche for $175 million in cash. InterMune will no longer be

Read the full 212 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE